Global Bone Marrow Market, By Transplantation Type (Allogeneic Bone marrow Transplantation, Autologous Bone Marrow Transplantation), Disease Indication (Lymphoma, Leukemia, Myeloma, Myelodysplasia, Aplastic Anemia, Sickle cell Anemia, Solid Tumors, Thalassemia, Myeloproliferative Neoplasms, Others), End User (Hospitals, Multi-Specialty Clinics, Ambulatory Surgical Centers) – Industry Trends and Forecast to 2031.
Bone Marrow Market Analysis and Size
Major factors that are boosting the growth of the bone marrow market in the forecast period are the growing incidences of non-Hodgkin and Hodgkin lymphoma, thalassemia, and leukemia, along with the common bone marrow diseases around the world, the developments in technology and the enhancing of the healthcare infrastructure. Furthermore, the advancing signs of bone marrow transplant for heart and neuronal disorders, increasing funding for logistic services, and the growing per capita healthcare expenses are some of the other factors anticipated to further propel the growth of the bone marrow market in the coming years. However, the high expenditure for the treatment, shortage of bone marrow donors, and instability of the repayment are a few of the factors further responsible for impeding the growth of the bone marrow market in the near future.
Data Bridge Market Research analyses that the global bone marrow market, which was USD 10, 541.69 million in 2023, would rocket up to USD 15,231.03 million by 2031 and is expected to undergo a CAGR of 5.40% during the forecast period. “Hospitals” dominate the end user segment of the market due to the convenience of consolidated medical services under one roof, streamlining patient care and making IMRT an attractive treatment option there. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Transplantation Type (Allogeneic Bone marrow Transplantation, Autologous Bone Marrow Transplantation), Disease Indication (Lymphoma, Leukemia, Myeloma, Myelodysplasia, Aplastic Anemia, Sickle cell Anemia, Solid Tumors, Thalassemia, Myeloproliferative Neoplasms, Others), End User (Hospitals, Multi-Specialty Clinics, Ambulatory Surgical Centers)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Spain, Turkey, U.K., Netherlands, Russia, Switzerland, Belgium, Hungary, Italy, Rest of Europe, China, India, Japan, Australia, South Korea, Malaysia, Singapore, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Agendia (U.S.), Agilent Technologies, Inc. (U.S.), Ambrilia Biopharma Inc. (U.S.), Astellas Pharma Inc. (U.S.), DiaDexus (U.S.), Illumina, Inc. (U.S.), QIAGEN (U.S.), F Hoffmann-La Roche Ltd (U.S.)Sanofi (France), Stryker Corporation (U.S.),PromoCell GmbH (Germany), STEMCELL Technologies Inc. (Canada), Lonza (U.S.), AllCells (U.S.), ATCC (American Type Culture Collection) (U.S.), Lifeline Cell Technology(U.S.), Conversant Bio (U.S.), HemaCare (U.S.), Mesoblast Ltd. (U.S.), Merck KGaA (Germany), Discovery Life Sciences (U.S.), ReeLabs Pvt. Ltd. ( India), Gamida Cell (Israel), among others
|
|
Market Opportunities
|
|
Market Definition
Bone marrow transplant also referred to as hematopoietic stem cell. It is a soft vascular tissue present in the interior of long bones. It comprises of two types of stem cells that are hematopoietic and mesenchymal stem cells. Bone marrow is mainly responsible for the haematopoiesis, (formation of blood cells), production of lymphocytes, and the storage of fats. The bone marrow transplant is the last alternative generally recommended by the physicians in the cases of fatal bone marrow diseases and bone or skin cancer.
Global Bone Marrow Market Dynamics
Drivers
- Increasing Incidence of blood disorders
The rising prevalence of blood-related disorders such as leukemia, lymphoma, and other haematological diseases is a significant driver for the bone marrow transplant market. For instance, according to data provided by the American Cancer Society, Inc., a voluntary health organization dedicated to eliminating cancer, it is estimated that about 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL in 2022 in the U.S., this includes both adults and children.
- Rising geriatric population
The aging population is more prone to conditions that may require bone marrow transplants, leading to an increased demand for these procedures. The rising cancer incidence and population ageing are two of the most important factors driving market growth. Furthermore, the elderly are more vulnerable to diseases, and life expectancy in developing countries has surpassed 80 years.
- Increasing research and development activities for bone marrow transplant
Chemotherapy or radiation suppresses the immune system and puts patients at high risk of infections, organ damage, and other life-threatening side effects. The method developed by the researchers at Washington University School of Medicine in St. Louis, U.S., takes an immunotherapeutic approach, combining the targeted elimination of blood-forming stem cells in the bone marrow with immune-modulating drugs to prevent the immune system from rejecting the new donor stem cells. This method could eliminate dangerously low blood cell counts, bleeding complications, organ damage, and infections. Thus, the market for bone marrow is being driven by a number of factors, including the adoption of bone marrow transplant which is growing in emerging markets due to increased healthcare spending and the expansion of healthcare infrastructure.
Opportunity
- Increasing technological advancements in bone marrow therapy to improve treatment
Advances in transplant technologies and techniques contribute to the growth of the market. Improvements in conditioning regimens, donor selection, and supportive care have enhanced the success rates of bone marrow transplants.
Moreover, advances in technology, improving healthcare infrastructure, emerging indications of bone marrow transplant for heart disorders, growing investment in logistic services are expected to increase, which in turn, will create lucrative market growth opportunities.
Restraint/Challenge
- High cost of treatment
The high cost of treatment is expected to restraint the market. Bone marrow transplant procedures can be expensive, including pre-transplant conditioning, the transplant itself, and post-transplant care. The high cost may limit access to these treatments for some patients. Moreover, bone marrow transplant procedures come with inherent risks, including infections, graft-versus-host disease, and other complications. The potential for adverse events may discourage some patients from pursuing transplantation that can be simply is projected to challenge the bone marrow market in the forecast period of 2024-2031.
This bone marrow market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bone marrow market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In September 2022 Scopio Labs launched the Full-Field Bone Marrow Aspirate (FF-BMA) application, which enables a complete digital workflow for bone marrow aspirate scanning and analysis
- In June 2022, The US FDA 510(k) approval was granted to launch MAXX-BMC in the United States, which Royal Biologics manufactures. MAXX-BMC is a bone marrow aspirate concentration system that provides users with an optimal sample of concentrated bone marrow aspirate from a patient at the point of care
Global Bone Marrow Market Scope
The bone marrow market is segmented on the basis of transplantation type, disease indication and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Transplantation Type
- Allogeneic Bone marrow Transplantation
- Autologous Bone Marrow Transplantation
Disease Indication
- Lymphoma
- Leukemia
- Myeloma
- Myelodysplasia
- Aplastic Anemia
- Sickle cell Anemia
- Solid Tumors
- Thalassemia
- Myeloproliferative Neoplasms
- Others
End User
- Hospitals
- Multi-Specialty Clinics
- Ambulatory Surgical Centers
Global Bone Marrow Market Regional Analysis/Insights
The bone marrow market is analyzed and market size insights and trends are provided by country, transplantation type, disease indication, and end user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.
Europe is expected to dominate the market because of the occurrence of the increasing number of innovative healthcare centers. Furthermore, the healthcare systems have introduced bone marrow transplants in their contributions and state-of-the-art public facilities, which will further boost the growth of the bone marrow market in the region during the forecast period.
North America is expected to witness significant growth during the forecast period of 2024 to 2031 due to the growing cases of chronic diseases such as blood cancer. Moreover, the increasing geriatric population is one of the factors anticipated to propel the growth of the bone marrow market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Bone Marrow Market Share Analysis
The bone marrow market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bone marrow market.
Some of the major players operating in the bone marrow market are:
- Agendia (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Ambrilia Biopharma Inc. (U.S.)
- Astellas Pharma Inc. (U.S.)
- DiaDexus (U.S.)
- Illumina, Inc. (U.S.)
- QIAGEN (U.S.)
- F Hoffmann-La Roche Ltd (U.S.)
- Sanofi (France)
- Stryker Corporation (U.S.)
- PromoCell GmbH (Germany)
- STEMCELL Technologies Inc. (Canada)
- Lonza (U.S.)
- AllCells (U.S.)
- ATCC (American Type Culture Collection) (U.S.)
- Lifeline Cell Technology (U.S.)
- Conversant Bio (U.S.)
- HemaCare (U.S.)
- Mesoblast Ltd. (U.S.)
- Merck KGaA (Germany)
- Discovery Life Sciences (U.S.)
- ReeLabs Pvt. Ltd. (India)
- Gamida Cell (Israel)
SKU-